Development of Antitumor Agents and P-Glycoprotein Inhibitors Focusing on Meroterpenoids

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K22727
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0801:Pharmaceutical sciences and related fields
• Research Institution: Gihu University of Medical Science
• Principal Investigator: FUKAYA MASASHI 岐阜医療科学大学, 薬学部, 助教 (70880417)
• Project Period (FY): 2020-09-11 – 2024-03-31
• Keywords: メロテルペノイド / テルペノイド / 構造決定

Outline of Final Research Achievements

Dipterocarpaceae plants are known to produce compounds called meroterpenoids, which are aromatic rings combined with terpenoids, and are known to be toxic to tumor cells. In this study, we focused on plants that produce meroterpenoids and terpenoids, especially those in the genus Eucalyptus, and isolated several dozen compounds. For those compounds obtained as novel compounds, physicochemical data were measured to clarify their structures.

Free Research Field

生薬学、天然物化学

Academic Significance and Societal Importance of the Research Achievements

医療の発展と共に高齢化社会になるにつれて悪性腫瘍の罹患者数が増大している．そこで問題になる点が，悪性腫瘍治療を継続することで薬剤耐性を獲得した難治性の腫瘍細胞の出現してしまうことであり，難治性の悪性腫瘍に対する治療薬の開発が強く望まれている．テルペノイドは，複数のキラル中心や酸素原子を持ち，その化学構造の多様性が特徴として挙げられる．テルペノイドと生体由来タンパク質は互いに水素結合や疎水性相互作用などを介して結合を形成することで相互作用を引き起こす．そこで，本研究では，テルペノイド含有植物素材から化合物の単離・精製・構造解析，殺細胞活性の評価を実施し，難治性抗悪性腫瘍候補薬の創出を目標とする．